Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
There's no money to replace most of NC students' laptops. What are schools doing about it?
Recommended
Ask the Meteorologist: What is a microburst & how did it cause damage in Wake, Johnston counties Sunday?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
56.95
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Week In Review: AffaMed Announced US Approval To Start Clinical Trials
February 19, 2022
AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to...
Via
Talk Markets
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
February 18, 2022
From
Legend Biotech
Via
Business Wire
FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients
February 15, 2022
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's...
Via
Benzinga
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
February 15, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
February 11, 2022
From
Legend Biotech
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
December 30, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Corporation Announces Pricing of Public Offering
December 16, 2021
From
Legend Biotech Corporation
Via
Business Wire
18 Stocks Moving in Thursday's Pre-Market Session
December 16, 2021
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...
Via
Benzinga
46 Biggest Movers From Yesterday
December 16, 2021
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
December 15, 2021
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 15, 2021
Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
December 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
December 15, 2021
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
December 15, 2021
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target....
Via
Benzinga
Legend Biotech Corporation Announces Proposed Public Offering
December 14, 2021
From
Legend Biotech Corporation
Via
Business Wire
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
December 13, 2021
Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted longer-term results from the Phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel...
Via
Benzinga
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
December 13, 2021
From
Legend Biotech
Via
Business Wire
Why Are Legend Biotech Shares Gaining Today?
December 07, 2021
Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese...
Via
Benzinga
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 07, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting
December 07, 2021
From
Legend Biotech
Via
Business Wire
KILL Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 06, 2021
Via
Business Wire
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 06, 2021
From
Legend Biotech
Via
Business Wire
80 Biggest Movers From Yesterday
November 17, 2021
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG)...
Via
Benzinga
53 Stocks Moving In Tuesday's Mid-Day Session
November 16, 2021
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG) shares climbed 35.5% to...
Via
Benzinga
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
November 16, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
November 04, 2021
From
Legend Biotech Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.